Human infectivity trait in <i>Trypanosoma brucei</i>: stability, heritability and relationship to sra expression by Turner, C.M.R. et al.
 
 
 
 
 
 
Turner, C.M.R. and McLellan, S. and Lindergard, L.A.G. and Bisoni, L. 
and Tait, A. and MacLeod, A. (2004) Human infectivity trait in 
Trypanosoma brucei: stability, heritability and relationship to sra 
expression. Parasitology 129(4):pp. 445-454.
 
 
 
 
 
 
 
http://eprints.gla.ac.uk/4584/ 
 
5th September 2008 
 
 
Glasgow ePrints Service 
https://eprints.gla.ac.uk 
Human infectivity trait in Trypanosoma brucei: stability, heritability and 
relationship to sra expression 
C. M. R. Turner1*, S. McLellan1, L. A. G. Lindergard1, L. Bisoni1,3, A. Tait2 and A. 
MacLeod2  
1. Division of Infection and Immunity, Institute of Biomedical and Life Sciences, 
Joseph Black Building, University of Glasgow G12 8QQ, UK 
2. Wellcome Centre for Molecular Parasitology, Anderson College, University of 
Glasgow, 56 Dumbarton Road, Glasgow G11 6NU, UK 
3. Current address: 
Wellcome Centre for Cell Biology, University of Edinburgh, Michael Swann 
Building, King's Building, Edinburgh EH9 3JR, UK 
* Corresponding author 
Tel: +44 141 330 6629 
FAX: +44 141 330 2041 
Email: m.turner@bio.gla.ac.ukT
SUMMARY 
Some Trypanosoma brucei lines infect humans whereas others do not because the 
parasites are lysed by human serum. We have developed a robust, quantitative in vitro 
assay based on differential uptake of fluorescent dyes by live and dead trypanosomes 
to quantify the extent and kinetics of killing by human serum. This method has been 
used to discriminate between three classes of human serum resistance; sensitive, 
resistant and intermediate. TREU 927/4, the parasite used for the T. brucei genome 
project, is intermediate. The phenotype is expressed in both bloodstream and 
metacyclic forms, is stably expressed during chronic infections and on cyclical 
transmission through tsetse flies. Trypanosomes of intermediate phenotype are 
distinguished from sensitive populations of cells by the slower rate of lysis and by the 
potential to become fully resistant to killing by human serum as a result of selection 
or long-term serial passaging in mice and to pass on full resistance phenotype to its 
progeny in a genetic cross. The sra gene has been shown previously to determine 
human serum resistance in T. brucei but screening for the presence and expression of 
this gene indicated that it is not responsible for the human serum resistance phenotype 
in the trypanosome lines that we have examined, indicating an alternative mechanism 
for HSR exists in these stocks. Examination of the inheritance of the phenotype in F1 
hybrids for both bloodstream and metacyclic stages from two genetic crosses 
demonstrated that the phenotype is co-inherited in both life cycle stages in a manner 
consistent with being a Mendelian trait, determined by only one or a few genes. 
 
Key words: Trypanosoma brucei, genome project, human infectivity, human serum 
resistance 
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INTRODUCTION 
  
Trypanosoma brucei, has been divided into three sub-species, T. b. brucei, T. b. 
rhodesiense and T. b. gambiense based on a combination of geographical distribution, 
host specificity and the course of infection in humans (chronic or acute). T. b. brucei 
is solely infective to animals including domestic livestock and game, T. b. 
rhodesiense infects humans and animals in East and Southern Africa, while T. b. 
gambiense infects humans and domestic animals in West and Central Africa (Hoare 
1972). An important aspect of research on this group of parasites has been to develop 
methods to distinguish these three morphologically identical sub-species so as to be 
able to identify the human infective sub-species in reservoir hosts and in the tsetse 
vector. Extensive analyses using a range of biochemical and molecular markers 
(Gibson 2002; Godfrey et al 1990; Matthieu-Daude et al 1995; Tait et al 1985) have 
largely been unable to identify consistent differences between the three sub-species 
with two exceptions; firstly, using both iso-enzyme and molecular markers, two 
distinct clades of T. b. gambiense could be defined (type 1 and 2) with type 2 being 
more closely related to West African T. b. brucei (Gibson 1986; Tait et al 1984). 
Second, in the Busoga focus in Uganda, it has been possible to define T. b. 
rhodesiense using multilocus genotypes as the sole criteria (Hide et al 1994; MacLeod 
et al 2000). 
  
The early observation that non-human infective isolates (T. b. brucei) are lysed by 
human serum and human infective isolates (T. b. gambiense and T. b. rhodesiense) are 
not, led to the development of the blood incubation infectivity test (BIIT), which can 
identify human infective isolates based on their ability to resist the lytic effects of 
human serum (Rickman and Robson 1970a). These authors showed that, in addition to 
fully resistant and fully sensitive trypanosomes, a class of ‘subresistant’ parasite 
isolates could be defined (Rickman and Robson 1970b). However, given these authors 
were not using cloned lines of trypanosomes, it was unclear whether this phenotype 
was the result of mixtures of resistant and sensitive trypanosomes or a distinct 
phenotype.  
 
The identification of the sra gene as exclusively expressed by human serum resistant 
(HSR) trypanosome lines and the demonstration that the gene can confer HSR when 
transfected into the bloodstream expression site (ES) of sensitive trypanosomes, has 
provided a further potentially valuable marker for the definition of human infective 
trypanosomes (Milner and Hajduk 1999; Xong et al 1998). The identification of sra 
as a determinant of resistance/sensitivity also solved the conundrum that human 
serum resistance is an unstable phenotype in at least some trypanosome stocks with 
different subclones being either sensitive or resistant. This variability of expression 
arises because the sra gene is expressed from an ES and thus expression of sra is 
linked to antigenic variation. There are multiple expression sites in the genome but the 
parasite uses only one ES at a time and switches use between ESs; which may or may 
not contain sra (Xong et al 1998). 
 
A PCR based method for the detection of the sra gene has been developed and the 
presence of the gene has been shown to correlate strongly with the human serum 
resistant (HSR) phenotype in the Busoga focus, and so this method has been heralded 
as a means of defining human infective trypanosomes (Welburn et al 2001). However, 
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while it is clear that the sra gene is responsible for human infectivity in a large 
number of T. b. rhodesiense isolates (Gibson et al 2002; Welburn et al 2001), there 
are exceptions to this in trypanosome lines from East Africa (Rifkin et al 1994; Agbo 
et al 2003) and, critically, this gene is not present in West African T. b. gambiense 
isolates (De Greef and Hamers 1994; Radwanska et al 2002). Thus there must be 
alternative mechanisms determining human infectivity/human serum resistance other 
than those based on the sra gene. 
 
The question arises as to whether these other mechanisms are likely to determine a 
phenotype that is a stable and heritable trait. Given the experience with sra these 
issues should not be assumed; sra expression is unstable and although the gene is 
inherited, it’s position in the genome is potentially variable by virtue of location in an 
ES. In this paper we report on the stability and heritability of the HSR phenotype in 
trypanosome stocks where it is not determined by sra.  
 
MATERIALS AND  METHODS 
 
Parasite stocks and lines  
Trypanosomes of five different genotypes were used in these studies as indicated in 
Table 1. Using the classical criteria of Hoare (1972), STIB 247 and TREU 927 were 
classified as T. b. brucei, ELIANE and STIB 386 are type 1 and type 2 T. b. 
gambiense respectively (Gibson, 1986), and the isogenic lines Etats 1.2 and 1.10 are 
T. b. rhodesiense clones derived from the stock EATRO 3 (Xong et al, 1998). STIB 
247, STIB 386, TREU 927 and EATRO 3 were transmitted separately through tsetse 
flies and metacyclic forms of TREU 927 were cloned as previously described (Turner 
et al 1990). STIB 386 and TREU 927 were also rapidly syringe-passaged between 
mice for 49 passages before recloning to generate lines that were human serum 
sensitive (HSS) and HSR, 386S and GUTat 10.1, respectively (Turner et al 1991; van 
Deursen et al 2001). A sub-line of TREU 927 was selected for human serum 
resistance by two rounds of incubating cells in 25 % human serum for four hours and 
inoculation of mice with 3 x 107 cells – TREU 927R.  We also used 74 F1 hybrid 
progeny from two genetic crosses, STIB 247 x TREU 927 and STIB 247 x STIB 386 
described previously (Turner et al 1990; MacLeod et al manuscript in preparation). 
Six of the progeny were transmitted separately through tsetse flies to generate 
metacyclic forms. 
 
In vitro human serum resistance assay 
In a series of preliminary experiments the following potential variables were 
investigated: serum from different individuals, the use of heat-inactivated/non heat-
inactivated serum, incubation temperature (25oC or 37oC), serum concentration, 
trypanosome density, source of control serum, duration of incubation, parasite 
viability staining methodology (data not shown). 
 
In our optimized assay, trypanosomes were isolated by differential centrifugation 
(Ghiotto et al 1979) rather than using anion exchange chromatography as the latter 
method always generated a ‘background’ of 5 – 20 % ‘dead’ cells. The cells were 
resuspended in a volume of 500l of either 25% human or guinea pig serum (Serotec) 
in PBS at a concentration of 1x107/ml and incubated at 37°C for 0, 2 and 4 hrs. The 
human serum was from a single individual after overnight fasting. The same donor 
was used for all assays. On completion of the incubation the suspension was 
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centrifuged at 900g for 5mins at 4°C, the pellet resuspended in 200l of nucleic acid 
staining solution (1 in 500 dilution of Syto 10 and Dead Red dyes in PBS; Molecular 
Probes) and incubated in the dark at room temperature for 15mins followed by 
centrifugation at 900g for 5mins. The cell pellet was resuspended in 50l of PBS 
followed by the addition of 400l of 4% glutataldehyde and fixation for at least 
15mins. At least 200 cells were scored as green or red using a fluorescence 
microscope and Zeiss filter set 9. These dyes stain the nuclei of viable cells green and 
those of dead cells red when they are viewed by fluorescence microscopy, thus 
allowing the number of viable and non viable cells to be measured. No double-labeled 
cells were detected and unlabeled cells comprised < 1% of the numbers counted in all 
assays.  
 
In vivo human serum resistance assay  
The assay we used was a minor variant of the Blood Incubation Infectivity Test 
(BIIT) (Rickman and Robson 1970a). Trypanosomes were separated from blood as 
above and diluted in MEM/Earles salts with 25% human serum from a single human 
donor to a final concentration of 1 x 107 cells ml-1. After incubation for 2-4 hrs at 
37°C, 100 cells, diluted in PBS, were inoculated intraperitoneally into each of two 
ICR mice, immunosuppressed by i.p. inoculation with 150 mgKg-1 
cyclophosphamide 24 hrs previously. Mice were screened for patent parasitaemias 6 
days a week for at least 2 weeks. A third mouse (positive control) in each experiment 
was inoculated with an equivalent number of parasites after incubation in 25 % 
guinea-pig serum under the same experimental conditions. 
 
DNA Preparation and PCR  
DNA was purified from bloodstream stage parasites using standard methods (Lanham 
and Godfrey 1970; Sambrook et al 1989). A PCR test of genomic DNA to verify the 
quality of the DNA stocks under investigation was carried out using primers TIM-C 
and TIM-D as described in MacLeod et al (1997). The PCR amplification of the sra 
gene was undertaken using the conditions and primers described in Radwanska et al 
(2002), Gibson et al (2002) and Welburn et al (2001). The products were separated on 
agarose gels and visualised under UV. The correct sized product for sra from STIB 
247 was excised from the gel under UV illumination then loaded onto a Spin-X 
column (Costar) and centrifuged at 15,000 rpm for 5 min. One microlitre of a 1/20 
dilution of the eluted DNA was amplified in a semi-nested reaction using primers SP-
A, 5’ ACAGCAACATCTCAGCGCTTTATGC and 538 (Welburn et al 2001). The 
PCR conditions were as follows: 95°C for 50 seconds, 58°C for 50 seconds and 64°C 
for 1 min for 30 cycles, using primer concentrations and the PCR buffer described 
elsewhere (MacLeod et al 1999). The products were cloned using the TA cloning kit 
(Invitrogen) and sequence determination carried out using the same primers and an 
ABI sequencer.  
 
Northern analysis 
Total RNA was prepared using the Trizol TM reagent (Gibco-BRL) according to the 
manufacturer’s instructions. The isolated RNA was treated with amplification grade 
DNAse 1 to remove contaminating DNA. For northern blots, 4g total RNA was 
denatured in formaldehyde and separated by agarose gel electrophoresis (Sambrook et 
al 1989). After separation, the RNA was transferred to Hybond nylon membrane 
using standard protocols, prehybridized in 7% SDS, 0.5M sodium phosphate pH 7.2, 
1mM EDTA, at 65°C for 2hrs followed by overnight hybridization with a random 
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primed probe (Sambrook et al 1989).  The probe for the sra gene was prepared by 
PCR amplification of genomic DNA from ETat1.10 using the primers and conditions 
described by Welburn et al (2001). In order to generate a tubulin probe, a 630bp 
fragment was amplified from DNA using the primers TUB 3’ 
GGGAATTCTTTCGCATCGAACATCTGCTGC and TUB 5’ 
GGGAATTCCCCCGACAACTTCATCTTTGGA, under the following conditions: 
95°C for 50 seconds, 55°C for 50 seconds and 64°C for 1 minutes for 30 cycles. 
 
RESULTS 
 
HSR phenotypes using in vivo assays of bloodstream forms 
An in vivo human serum resistance assay was used to determine the serum resistance 
profile of three stocks used as parents in genetic crosses. Using an inoculum of 100 
parasites per mouse, STIB 247, previously reported as human serum sensitive (Brun 
and Jenni 1987) failed to infect any of 10 mice and STIB 386 infected all 10 mice as 
expected. TREU 927, however, infected only 2 out of 8 mice, an outcome previously 
described for other field stocks and termed ‘subresistant’ (Hawking 1973; Rickman 
and Robson 1970b). At a higher inoculum (1000 cells), STIB 247 still failed to infect 
any of 8 mice whereas TREU 927 now infected all 8 mice. Equal numbers of 
trypanosomes were incubated with guinea pig serum prior to inoculation in TO mice, 
as controls, which resulted in all mice becoming infected. The results are summarized 
in Table 1. 
 
HSR phenotypes using in vitro assays  
We first analysed the serum resistance profile of the stocks STIB 386, TREU 927 and 
STIB 247 in this assay to compare with the in vivo data. The fluorescent staining of 
these stocks is shown in Figure 1, and the percentage death depicted graphically in 
Figure 2A. To verify this new assay we also tested a number of reference lines. The 
HSR stock, ELIANEand three isogenic lines of T.b. rhodesiense, EATRO 3, Etat 1.2 
and Etat 1.10, the latter two having previously been described as being HSS and HSR, 
respectively (De Greef and Hamers 1994; Rifkin et al 1994; Xong et al 1998). These 
results are summarized in Table 1.  The results for these lines are also shown in 
Figure 2A. Lines Etat 1.2 and STIB 247 were examples of the HSS phenotype class, 
with a substantial loss of viability (>90%), while ELIANE and Etat 1.10 were 
resistant to human serum with only ~18% loss of viability over a four hour incubation 
period. However, TREU 927 and EATRO 3 both showed intermediate kinetics of 
lysis over the 4hr time course. These data are consistent with those obtained with the 
in vivo assay and confirm that intermediate resistance is a definable phenotype, 
distinct from either resistance or sensitivity. To address the formal possibility that the 
intermediate phenotype could be due to a mixture of cells either expressing or not 
expressing human serum resistance, a 1:1 mixture of HSR (STIB 386) and HSS (STIB 
247) trypanosomes was assayed as before and resulted in ~50% lysis and different 
lysis kinetics compared with those obtained for the intermediate phenotype (figure 
2A). Based on these results, we conclude that in addition to the phenotypes of human 
serum sensitivity and resistance, a third phenotype of intermediate resistance can be 
defined by both in vivo and in vitro assays.  
To determine if the human serum resistance phenotypes are stable through the course 
of chronic infections, we initiated infections of STIB 247, STIB 386 and TREU 927 
in groups of mice and at weekly intervals assayed populations of trypanosomes. Over 
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a five week period for STIB 247 and a three week period for each of the other two 
stocks, the HSR phenotypes were unchanged for each stock (data not shown). 
 
Human serum resistance in metacyclic trypanosomes 
 To determine whether the human serum resistance phenotype was the same in 
metacyclic forms as in bloodstream forms, we transmitted EATRO 3, STIB 247, 
STIB 386 and TREU 927 through tsetse flies, isolated metacyclic forms directly from 
the salivary glands and determined their human serum resistance profiles using the in 
vitro assay. The results, presented in Figure 2B and summarized in Table 1, are 
directly comparable to those in Figure 2A and show that the metacyclic forms of each 
stock had the same resistance phenotype as the bloodstream stages. EATRO 3 and 
TREU 927 were intermediate, STIB 386 was resistant and STIB 247 was sensitive to 
lysis by human serum. In all cases, the percentage lysis was slightly higher for 
metacyclic than for bloodstream forms. This can be attributed to the method of 
isolating metacyclic forms as they will be contaminated with pre-metacyclic 
trypanosomes which would be lysed by the alternative pathway of complement.  
 
To further investigate the intermediate phenotype of stock TREU 927, single 
metacyclic forms of the parasites were optically isolated from the salivary glands of 
tsetse flies and amplified in mice. The resultant sub-cloned bloodstream populations 
were analyzed for human serum resistance using the in vitro assay and all had an 
intermediate phenotype equivalent to that observed for TREU 927 before fly 
transmission (data not shown). These results show that the intermediate phenotype is 
a genuine third phenotypic state which is stable after fly transmission and subsequent 
expansion in mice.  
 
Stability of human serum resistance 
The instability of the human serum resistance phenotype on passaging in mice has 
been previously described for some T. b. rhodesiense stocks, including EATRO 3 (De 
Greef and Hamers 1984; Hajduk et al 1989; Rifkin et al 1994; Xong et al 1998). The 
resistance phenotypes of STIB 247, TREU 927 and STIB 386 are stable through the 
natural life cycle of the trypanosomes, i.e. in chronic infections and on fly 
transmission, but it is possible that their phenotype could change on serial 
bloodstream syringe passage. To investigate human serum resistance stability in these 
stocks we examined their ability to firstly, change phenotype on long term passaging, 
followed by sub-cloning and second, under selection for resistance. The line GUTat 
10.1, which is being used for the T. brucei genome sequencing project, changed HSR 
phenotype from intermediate to resistant (Table 1). Also, just two rounds of selection 
of TREU 927 for 4 hours in human serum caused an equivalent change in phenotype, 
to generate the line TREU 927R. We attempted to select HSR STIB 247 lines in the 
same manner, but without success. Long term passaging of STIB 386 and sub-cloning 
led to identification of a sub-clone that was sensitive to lysis by human serum (STIB 
386S, Table 1). These results indicate that the HSR phenotype is a variable trait in the 
intermediate and resistant stocks, but is invariant in the sensitive stock, STIB 247. To 
investigate this last result further, 11 different lines which were sensitive to human 
serum, as determined by the in vitro assay, were selected in human serum in an 
attempt to generate resistant lines. No resistant trypanosomes were isolated (data not 
shown).  
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Presence/absence of the sra gene 
In order to test if the sra gene is present in the stocks under investigation in this study, 
we attempted to amplify this gene by PCR, using the PCR test described in Welburn 
et al (2001). A sequence homologous to the sra gene, which has been identified in 
TREU 927 on chromosome II and shown to be a VSG pseudogene (Campillo and 
Carrington 2003), was amplified from all stocks using this test. Since this generates a 
larger sized product than the sra gene it acts as an internal control for PCR 
amplification (figure 3A). The 743bp product derived from the sra gene was 
amplified from Etat 1.10 and Etat 1.2 as expected. The PCR assay failed to amplify 
sra from TREU 927 and STIB 386, although a series of products was amplified from 
STIB 247. To identify if any of these products was from the sra gene, semi-nested 
PCR was performed on gel-extracted DNA using primers SP-A and 538. A single 
product of the expected size (576bp) was obtained. To establish the relationship 
between the amplified products and the sra gene sequence, this amplified fragment 
was cloned and sequenced. The fragment obtained from STIB 247 showed 99.5% 
identity to the published sequence (data not shown). This level of homology suggests 
that the PCR product from STIB 247 is the sra gene. Further attempts to amplify the 
sra gene from TREU 927 and STIB 386 using alternative primer combinations 
(Gibson et al 2002; Radwanska et al 2002) failed to produce a product, although 
amplification of the expected product in the positive controls was observed (Table 1). 
As a positive control to demonstrate that the DNA samples contained amplifyable 
DNA, the tim gene was amplified by PCR from each stock under the conditions 
described previously (MacLeod et al 1997). The expected sized product was obtained 
for all samples (data not shown). These data suggest that TREU 927/GUTat 10.1 and 
STIB 386 do not contain the sra gene despite being HSR.   
 
Expression of the sra gene in bloodstream forms 
In order to test whether the sra gene in STIB 247 was expressed, northern blot 
analysis was undertaken. Etat 1.10 and Etat 1.2  were used as positive and negative 
controls (Xong et al 1998). TREU 927,lineTREU 927R,   STIB 386 and STIB 386S 
were also included in this analysis. The probe was a 575bp fragment of the sra gene 
amplified from Etat 1.10 genomic DNA, which was sequenced to confirm it was part 
of the sra gene (data not shown). The results, shown in figure 3B(i), revealed a strong 
hybridization signal for Etat 1.10 but no signal for ETAT 1.2 or from STIB 247. 
Similarly, no signal was observed with either STIB 386 (either resistant or sensitive) 
or TREU 927 (either resistant or intermediate), suggesting that the human serum 
resistance expressed by these stocks is not determined by the sra gene. A tubulin 
probe was used as a control for loading (figure 3B(ii)). The results are summarized in 
Table 1. 
 
Inheritance of HSR 
 An investigation into the inheritance of the phenotype was undertaken to determine if 
the ability to resist the lytic effects of human serum is a trait that is inherited in a 
Mendelian fashion. The HSR phenotypes of a series of F1 hybrids (bloodstream 
forms) from two genetic crosses (previously described in Tait et al (2002) were 
analyzed using the in vitro assay. Some of the results are presented in figure 4A and 
indicate that all the progeny from the STIB 247 x STIB 386 cross and the STIB 247 x 
TREU 927 cross fall into one of three discrete categories either sensitive, resistant or 
intermediate, and not a range of different levels of resistance; thus the phenotype 
segregates in the cross. For the STIB 247 (sensitive) x STIB 386 (resistant) cross, 8 
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were HSR, 14 were HSS and 12 were intermediate and for the STIB 247 (sensitive) x 
TREU 927 (intermediate) cross, 10 progeny were HSR, 11 were HSS and 17 were 
intermediate in phenotype. It is clear, therefore, that the phenotype is inherited in a 
manner consistent with being a Mendelian trait, and that only one or a few genes 
determine the phenotype. As STIB 247 is invariably sensitive to human serum, the 
resistant hybrids presumably inherited the ability to resist human serum from the other 
parent, either TREU 927 or STIB 386. Therefore, TREU 927 can confer full 
resistance as well as intermediate resistance to its progeny and STIB 386 can pass on 
intermediate resistance as well as full resistance to its progeny. 
In order to determine if the same phenotype is expressed in metacyclic form hybrids 
from the STIB 247 x TREU 927 cross were transmitted through tsetse flies and 
metacyclics tested. The human serum resistance profiles were the same for metacyclic 
forms as for bloodstream forms, indicating that the inherited phenotypes are stable on 
fly transmission and that the same gene(s) are likely to be responsible for both 
bloodstream and metacyclic HSR (figure 4B).  
 
DISCUSSION 
 
The BIIT assay (Rickman and Robson 1970a) was the first technique which could 
differentiate T. b. brucei from T. b. rhodesiense, by assaying the ability of 
trypanosomes to survive in human serum and subsequently infect mice. A number of 
in vitro assays have been developed since then that discriminate trypanosome lines as 
HSR or HSS (c.f. Brun and Jenni 1987; Hajduk et al 1989; Tomlinson et al 1995). In 
this paper, we describe a simple, robust quantitative method which directly measures 
the survival of trypanosomes in human serum and that discriminates the response to 
human serum into three phenotype classes – sensitive, resistant and intermediate. The 
intermediate phenotype is defined by a slower rate of parasite killing than that 
observed with the sensitive phenotype. The comparison of our in vitro and in vivo 
data suggests that the intermediate phenotype may correspond to the ‘subresistant’ 
class previously described using the BIIT (Rickman and Robson 1970a; Hawking 
1977) 
 
What is the biological significance of the intermediate phenotype? At first glance, the 
similarity between the intermediate and HSS phenotypes is such that the intermediate 
phenotype could be considered a slower form of HSS. However, three lines of 
evidence demonstrate that the distinction between sensitive and intermediate is 
biologically important. Trypanosomes with intermediate sensitivity were capable of 
becoming fully resistant by (1) rapid selection, (2) by long term passaging and 
recloning and (3) can pass on a resistant phenotype to progeny in a genetic cross 
between parents of intermediate and sensitive phenotypes.  
 
Our discrimination of three phenotype classes and the demonstration in this paper and 
by others (De Greef and Hamers 1994; Hajduk et al 1989) that lines of trypanosomes 
can be developed that differ in phenotype from that of the stocks from which they 
originated calls into question the biological validity of the subspecies definitions used 
for T. brucei. This is because the classical criterion to discriminate T. b. brucei  from 
T. b. rhodesiense and T. b. gambiense is the ability to infect humans (Hoare 1972). In 
light of this ambiguity we denote some of the subspecies definitions in Table 1 with 
question marks. How the subspecies definition issue might be resolved is important 
but falls outwith the scope of this current paper. 
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We have shown that the serum resistance phenotype is stable through the course of 
chronic infections, after cyclical transmission through tsetse flies and is the same in 
both bloodstream and metacyclic forms. The only occasions in which we have found 
the trait to be variable is under selection pressure and in the artificial laboratory 
situation of long-term serial passaging between mice (for intermediate and resistant, 
but not sensitive, lines). This variability has been noted before (De Greef and Hamers 
1994; Hajduk et al 1989) and indeed has been exploited extremely successfully to 
create isogenic pairs of sensitive and resistant lines, comparison of which has led to 
the identification of a gene, sra, that can determine resistance/sensitivity (De Greef 
and Hamers; 1994, Xong et al 1998; Milner and Hajduk 1999). It is possible that the 
mechanism of variability is common to many stocks irrespective of whether a sra or 
non-sra mode of action is employed to determine human serum resistance. 
 
The identification of sra as a determinant of resistance in T. b. rhodesiense has 
resulted in the use of a simple PCR assay to distinguish between human serum 
sensitive and resistant trypanosomes (Gibson et al 2002; Radwanska et al 2002; 
Welburn et al 2001), as opposed to the lengthy and costly BIIT (Rickman and Robson 
1970a). This PCR test is based on the assumption that human serum resistant 
trypanosomes have the sra gene and non-human infective trypanosomes do not which 
appears to hold true for the majority of isolates tested from east and southern Africa 
(Gibson et al 2002; Welburn et al 2001; Agbo et al 2003), but not for west and central 
Africa  (Berberof et al 2001; Radwanska et al 2002). 
 
In order to determine the relevance of the sra gene to the human serum resistance 
phenotypes described here, the PCR tests of Gibson et al (2002) and Welburn et al 
(2001) were used to determine if the sra gene is present in the stocks which were 
identified as HSR, HSS and intermediate. The HSS stock, STIB 247, tested positive 
for the sra gene (confirmed by sequence analysis) whereas the HSR and intermediate 
stocks, STIB 386 and TREU 927 were both negative.   The sequence homologous to 
the sra gene, which has been identified in TREU 927 and is present in all isolates 
tested here, is a pseudogene it cannot be responsible for the HSR phenotype 
(Campillo and Carrington 2003). This clearly indicates that a test for the 
presence/absence of the sra gene, while being a good approximation, is not an 
absolute test to predict the phenotype of HSR and that alternative mechanisms for 
HSR exist not only in West African stocks (Berberof et al 2001; Radwanska et al 
2002) but also in the East African TREU 927 isolate. The lack of correlation between 
human serum resistance and expression of the sra gene was further confirmed by 
northern analysis, which demonstrated that neither STIB 386 nor TREU 927 lines 
expressed the sra gene or a related sra homologue. The HSR phenotype of these 
stocks is also expressed in the metacyclic stage which suggests that the gene 
determining resistance is unlikely to be expressed from a bloodstream expression site, 
as is the case for the sra gene, as bloodstream expression sites are not thought to be 
transcribed at the metacyclic stage (Graham et al 1990). It is formally possible that 
low level transcription of the sra gene could occur to the extent that it confers HSR 
but is not detectable by northern analysis. However, the fact that no sra gene was 
detected by three independent PCR tests would suggest that the gene is not present in 
these stocks and so cannot be expressed or is so divergent that it cannot be amplified 
by a PCR test or detected by hybridisation. It is possible that both the sra mechanism 
and the alternative mechanism of HSR are present and functioning in the same 
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organism. Indeed, the clone EATRO 3 has an intermediate phenotype and so, 
presumably, is expressing resistance from the alternative mechanism, (as expression 
of the sra gene confers full resistance), while its derivative, Etat 1.10 is fully resistant 
by expressing sra. 
 
These results presented here clearly demonstrate that the human serum resistance 
phenotype of the stocks under study is not due to the expression of the sra gene but 
due to an alternative mechanism. To determine the genetic basis of this mechanism, 
the inheritance pattern of resistance was investigated by the analysis of a series of F1 
hybrids from two genetic crosses, STIB 247 x TREU 927 and STIB 247 x STIB 386. 
It would have been interesting to investigate inheritance in the cross TREU 927 x 
STIB 386 but unfortunately there are too few F1 hybrids available to be informative 
(Turner et al 1990).  For both crosses, the F1 hybrids fell into one of three 
phenotypes, fully resistant, fully sensitive or intermediate, demonstrating that this 
phenotype segregates in the hybrids and is potentially amenable to linkage analysis. A 
genetic map of TREU 927 is currently being generated with the first two 
chromosomes, I and II, having been completed (El Sayed et al 2003; Hall et al 2003). 
Thus it should be possible to identify markers in the genetic map which cosegregate 
with the phenotype, and so the region of the genome harbouring the gene which 
determines human serum resistance can be located. A similar analysis of a cross STIB 
386 x STIB 247 should allow us to map and identify the gene(s) responsible for the 
HSR phenotype in West African human infective trypanosomes. 
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FIGURE LEGENDS 
Figure 1. Three stocks of T. brucei parasites incubated for four hours in human serum 
and stained using Syto 10/Dead Red. A, STIB 247 trypanosomes were killed by 
human serum and stained red; B, STIB 386 cells were largely resistant to human 
serum and stained green and C, TREU 927 cells gave an intermediate result. 
Figure 2. A quantitative analysis of human serum resistance/sensitivity in lines of T. 
brucei. A, the kinetics of killing of bloodstream TREU 927 (?) is intermediate 
between that of STIB 247 (?, T.b. brucei) and STIB 386 (?, T.b. gambiense type 2) 
and different from the kinetics of killing of a 1:1 mixture of resistant and sensitive 
bloodstream trypanosomes (?). B, the kinetics of killing of metacyclic forms of STIB 
247 (?), STIB 386 (?), TREU 927 (?) and EATRO 3(?). Average values are 
shown, n = 3, 2SE < 10% in all cases. Lysis in parallel incubations in Guinea-pig 
serum as negative controls <10% in all cases. 
Figure 3. A, PCR amplification of the sra gene using primers and conditions 
described in Welburn et al (2001). PCR products from the lines STIB 247, Etat 1.10, 
Etat 1.2, TREU 927, TREU 927R, STIB 386R and STIB 386S were separated on a 
1% Seakem agarose gel and visualized by eithidium bromide staining. The 1085bp 
product is the related VSG pseudogene and the 743bp band is the sra gene (Campillo 
and Carrington 2003). B (i), The sra gene probe was hybridized with a northern blot 
of total RNA (4g per track). Exposure time was 4 hours. (ii), Ethidium stained gel of 
the RNA prior to northern blotting. (iii) The northern blot was reprobed with a tubulin 
probe as a positive control. 
Figure 4. A, The kinetics of killing of bloodstream form F1 hybrids from a STIB 247 
x TREU 927 cross. B, The kinetics of killing of metacyclic forms of the same hybrids. 
F532/63bcl3(?) and 5(?),  F532/72mcl1(?), 4(?), 5(?) and 9(?). Average values 
are shown, n = 3, 2SE < 10% in all cases. Lysis in parallel incubations in Guinea-pig 
serum as negative controls <10% in all cases. 
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Table 1 Human serum resistance phenotypes and sra expression and genotypes of 
trypanosome lines. STIB 386S is a subclone of STIB 386,  GUTat 10.1 a subclone of 
TREU 927 and Etats 1.2 and 1.10 are subclones of EATRO 3. Human serum resistant 
clones are defined here as T. b. rhodesiense and human serum sensitive clones as T. b. 
brucei. A = wild animal, H = human, T = tsetse, S = sensitive, I = intermediate, R = 
resistant. ‘?’ indicates equivocal subspecies definition as discussed in the text. 
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Table 1 
HSR assay 
 
SRA assay 
Stock Host Subspecies 
Bloodstream 
forms 
Metacyclic 
forms 
   
In 
vivo 
In vitro In vitro 
Presence 
of SRA 
gene by 
PCR 
Expression 
of SRA by 
northern 
analysis 
STIB 247 A T.b. brucei S S S + - 
STIB 386 H T.b.gambiense, type 
2 
R R R - - 
  STIB 386S H 
T.b.gambiense, type 
2? 
S S  - - 
TREU 927 T 
T.b. brucei? 
I I I - - 
 TREU 927R T T.b. rhodesiense? R R  - - 
  GUTat10.1  T 
T.b. rhodesiense? 
 R    
ELIANE H T.b.gambiense, type 
1 
 R  -  
EATRO 3  T T.b. rhodesiense?  I I + - 
      Etat 1.2 T T.b. brucei?  S  + - 
      Etat 1.10 T T.b. rhodesiense?  R  + + 
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